strong soliri data anoth indic
announc posit top-line result phase prevent studi soliri
patient auto antibody-posit neuromyel optica
spectrum disord nmosd met primari endpoint demonstr reduc
risk nmosd relaps compar placebo soliri also achiev
patient relaps free week compar placebo soliri reduc
annual relaps rate compar placebo secondari endpoint
disabl benefit qualiti life measur favor soliri differ
compar placebo small like due natur diseas
look confirm benefit open label extens trial safeti profil
soliri studi broadli consist seen previou soliri studi
note case meningococc infect look forward
detail result futur medic congress
given strong efficaci safeti data prevent plan engag
regulatori author come month discuss data file requir
intend includ approxim patient worth open-label
extens studi data file packag await feedback fda file
requir optimist given solid efficaci safeti result
nmosd provid upsid current estim
soliri previous demonstr encourag efficaci nmosd phase
studi trial small uncontrol expect posit outcom
prevent somewhat mediat thu think room potenti upsid
current revenu estim driven nmosd sale increas probabl
approv ro base posit phase readout adjust po
accordingli reiter buy alxn averag growth
net dbt
full definit iqmethod sm measur see page
bofa merril lynch seek busi issuer cover research report
result investor awar firm may conflict interest could
affect object report investor consid report singl
factor make invest decis
refer import disclosur page analyst certif page price object
basis/risk page
return capit employ
return equiti
iqmethod sm qualiti earn
net incom cont oper
chang work capit
full definit iqmethod sm measur see page
biotechnolog compani market
soliri monoclon antibodi therapi
treatment ultra-rar diseas includ
paroxysm nocturn hemoglobinuria pnh
compani also market strensiq treatment
hypophosphatasia kanuma lal-d
focu sever life threaten ultra rare
rate buy expect industri
growth compani market product soliri
success launch new product
strensiq kanuma see upsid risk street
estim addit pipelin
momentum creat news flow
price object base discount cash flow analysi use
wacc termin growth rate
downsid risk failur meet expect soliri sale and/or launch
strensiq asfotas alfa kanuma lal-d govern drug price
focu ultra-orphan product failur advanc key pipelin product includ
soliri new indic
ying huang herebi certifi view express research report accur
reflect person view subject secur issuer also certifi
part compens directli indirectli relat specif
recommend view express research report
qualiti earn
iqmethod smi set bofa merril lynch standard measur serv maintain global consist three broad head busi perform qualiti earn valid key featur
iqmethod consist structur detail transpar methodolog guidelin maxim effect compar valuat process identifi common pitfal
iqdatabas real-tim global research databas sourc directli equiti analyst earn model includ forecast well histor data incom statement balanc sheet cash
flow statement compani cover bofa merril lynch
iqprofil sm iqmethod sm servic mark america corpor iqdatabas regist servic mark america corpor
